IsoDerm CBD: Novel Non-Systemic Cannabinoid Therapy

MAJOR ANNOUNCEMENT ON CANNABINOID THERAPY

For individuals and families seeking cannabinoids (parts of the cannabis plant) for neurologic, psychiatric and pain conditions take note and spread the word.

 

Indications in these three main categories include:

  • Spasticity
  • muscle spasms
  • tremor
  • headache
  • neuropathies and neuropathic pain
  • seizures
  • anxiety
  • attentional and focus problems
  • cognitive blunting
  • social isolation
  • impulsivity
  • agitation
  • insomnia
  • fibromyalgia symptoms
  • nervous tics
    … and more.

A major announcement will be made on cannabinoids, how these unique parts of the cannabis plant work, and how consumers can take immediate advantage of this news in the U.S. and around the world.
Presented by Dr. Ronald Aung-Din at the American Academy of Anti-Aging Medicine (A4M) World Congress in Las Vegas, the announcement will be made on Friday, December 9th at 5:30 p.m. in the main exhibit hall. Admission is included with ticket purchase (see A4M website for admission details.)

Dr. Aung-Din will explain the following cannabinoid therapy breakthrough:

“IsoDerm CBD: Novel Non-Systemic Cannabinoid Therapy”

  • Novel, proprietary delivery of cannabinoids using direct nerve connections of skin to central nervous system (CNS), without blood flow requirements and restrictions of blood-brain barrier
  • Therapeutic benefits as cannabinoid receptors in skin free nerve-endings are activated by topical applications at strategic locations
  • Therapeutic benefits observed in less than 10-15 minutes without systemic side effects or drug interactions
  • Uses of universally available, unregulated hemp-derived cannabinoids
  • Clinically observed to benefit a wide range of neurologic, psychiatric, and pain conditions; including: spasticity, muscle spasms, tremor, headache, neuropathies and neuropathic pain, seizures, anxiety, attentional and focus problems, cognitive blunting, social isolation, impulsivity, agitation, insomnia, fibromyalgia symptoms, nervous tics, and others
  • May be purchased OTC without prescription; but should be used with medical supervision, if prior traditional medications are to be tapered as result of clinical improvement with Direct Effects Therapy
  • Patents filed with USPTO and foreign patent offices; seven separate patents granted related to Direct Effects Therapy

 

About Dr. Ronald Aung-Din

Dr. Ronald Aung-Din has practiced General Neurology & Neuro-Psychiatry in Sarasota, FL over 25 years. He is board-certified by American Board of Psychiatry & Neurology and member, American Academy of Neurology.

After studies in Mechanical and Environmental Engineering at Bucknell (Lewisburg, PA) and Cornell (Ithaca, NY) Universities, he worked for a period in industry as supervising engineer. He then attended Columbia University in New York City for Premedical studies, followed by Medical School at University of Texas Southwestern Medical School, Dallas, TX. Residencies in Neurology and Neurosurgery were at University of Florida, Gainesville, FL. Additional studies included a Medical Student Fellowship in Cardiology at Radcliffe Infirmary, Oxford and Clinical Neurology Postgraduate Fellowship at National Hospital for Nervous Disease, Queen Square, London, UK.

Through his affiliation with Lovelace Scientific Resources, Inc., Albuquerque, NM and his own clinical practice, he has participated in over 60 pharmaceutical industry-sponsored clinical trials. He currently functions as Principal Investigator in a number of ongoing drug research studies in MS, epilepsy, pain, Parkinson’s disease, and other neurological diseases.

Dr. Aung-Din is also active in treating varied neurological and psychiatric conditions using delivery of CNS-active drugs with Direct Effects topical delivery, a technology developed by him for which 7 patents have to date been granted in the United States, Europe, and Australia; with others pending.

Publications using this novel therapy in migraine, Parkinson’s disease, and diabetic neuropathy appeared in Drug Delivery Technology, Vol.10. No 8, p. 48, October 2010 and Drug Delivery Technology, Vol. 9. No 9, p. 44, October 2009, www.drugdeliverytech.com; and in June 2015 www.drug-dev.com: “THERAPEUTIC FOCUS – Direct Effects™ Diabetic Neuropathy Therapy: Treating Symptoms & Modifying Disease.”

Direct Effects topical drug delivery is unique in that therapeutic effect occurs through cutaneous free-nerve endings with direct afferent connections to CNS. As such, general circulation and blood-brain-barrier are bypassed, with avoidance of systemic side effects and drug interactions. AfGin Pharma, LLC was founded by Dr. Aung-Din in 2009 to advance this unique technology and its goal of “Enhanced Neuro-Therapeutics through Direct Effects Topical Technology;” website: afginpharma.com.
Isodiol is a trusted community outreach partner. The Company sponsors key messages that educate the public. If you are not able to attend the A4M conference but would like additional information on Dr. Ronald Aung-Din’s presentation on “IsoDerm CBD: Novel Non-Systemic Cannabinoid Therapy”, contact [email protected] for details.